Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan
CONCLUSIONS: Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.PMID:38679657 | DOI:10.1007/s12282-024-01572-8 (Source: Breast Cancer)
Source: Breast Cancer - April 28, 2024 Category: Cancer & Oncology Authors: Akihiko Shimomura Yasuaki Sagara Ryo Koto Masakazu Fujiwara Yuka Kanemura Hiroshi Kitagawa Shigehira Saji Source Type: research
Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan
CONCLUSIONS: Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.PMID:38679657 | DOI:10.1007/s12282-024-01572-8 (Source: Breast Cancer)
Source: Breast Cancer - April 28, 2024 Category: Cancer & Oncology Authors: Akihiko Shimomura Yasuaki Sagara Ryo Koto Masakazu Fujiwara Yuka Kanemura Hiroshi Kitagawa Shigehira Saji Source Type: research
Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan
CONCLUSION: Cryoablation for ESBC is an effective and safe procedure with excellent cosmetic outcomes and improved QoL. This study contributes to the growing evidence supporting cryoablation as a potential standard treatment for ESBC, given compliance to pre-defined patient selection criteria.PMID:38678120 | DOI:10.1007/s12282-024-01584-4 (Source: Breast Cancer)
Source: Breast Cancer - April 27, 2024 Category: Cancer & Oncology Authors: Hisanori Kawamoto Koichiro Tsugawa Yuko Furuya Kaori Sakamaki Sayoko Kakimoto Mina Kitajima Mariko Nagai Takishita Mizuho Tazo Mari Hara Nakano Takako Kuroda Ayaka Shimo Arata Shimo Yasuyuki Kojima Makiko Tsuzuki Ai Motoyoshi Ei Haku Toru Nishikawa Yoshih Source Type: research
Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis
CONCLUSIONS: Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.PMID:38671211 | DOI:10.1007/s12282-024-01586-2 (Source: Breast Cancer)
Source: Breast Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Soo Jin Lee Chihwan David Cha Hanpyo Hong Yun Young Choi Min Sung Chung Source Type: research
Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis
CONCLUSIONS: Our meta-analysis demonstrated that adjuvant tamoxifen therapy in premenopausal patients caused bone loss after 3 years of follow-up, especially at the lumbar spines. For a definite evaluation of the adverse effects of tamoxifen on bone, it is necessary to accumulate more relevant studies.PMID:38671211 | DOI:10.1007/s12282-024-01586-2 (Source: Breast Cancer)
Source: Breast Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Soo Jin Lee Chihwan David Cha Hanpyo Hong Yun Young Choi Min Sung Chung Source Type: research
Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors
CONCLUSION: Our study revealed that plasma metabolites were significantly different between recurrent and non-recurrent patients, proposing therapeutic insights for breast cancer prognosis.PMID:38652345 | DOI:10.1007/s12282-024-01579-1 (Source: Breast Cancer)
Source: Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Pei-Jing Yang Eing-Mei Tsai Ming-Feng Hou Yen-Jung Lee Tsu-Nai Wang Source Type: research
Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors
CONCLUSION: Our study revealed that plasma metabolites were significantly different between recurrent and non-recurrent patients, proposing therapeutic insights for breast cancer prognosis.PMID:38652345 | DOI:10.1007/s12282-024-01579-1 (Source: Breast Cancer)
Source: Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Pei-Jing Yang Eing-Mei Tsai Ming-Feng Hou Yen-Jung Lee Tsu-Nai Wang Source Type: research
Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors
CONCLUSION: Our study revealed that plasma metabolites were significantly different between recurrent and non-recurrent patients, proposing therapeutic insights for breast cancer prognosis.PMID:38652345 | DOI:10.1007/s12282-024-01579-1 (Source: Breast Cancer)
Source: Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Pei-Jing Yang Eing-Mei Tsai Ming-Feng Hou Yen-Jung Lee Tsu-Nai Wang Source Type: research
Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors
CONCLUSION: Our study revealed that plasma metabolites were significantly different between recurrent and non-recurrent patients, proposing therapeutic insights for breast cancer prognosis.PMID:38652345 | DOI:10.1007/s12282-024-01579-1 (Source: Breast Cancer)
Source: Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Pei-Jing Yang Eing-Mei Tsai Ming-Feng Hou Yen-Jung Lee Tsu-Nai Wang Source Type: research
Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients
Breast Cancer. 2024 Apr 22. doi: 10.1007/s12282-024-01587-1. Online ahead of print.NO ABSTRACTPMID:38647866 | DOI:10.1007/s12282-024-01587-1 (Source: Breast Cancer)
Source: Breast Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Kadri Altundag Source Type: research
Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy
Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01571-9. Online ahead of print.ABSTRACTCirculating tumor DNA (ctDNA) consists of DNA fragments released from cancer cells into the blood circulation with quick clearance. Analysis of ctDNA can enable real-time assessment of the presence of cancer cells and their genomic characteristics. Therefore, ctDNA is expected to be one of the most useful biomarkers for cancer. In recent years, several ultra-sensitive assays for ctDNA analysis have been developed, and many clinical trials are using these assays to investigate the efficacy of ctDNA-based therapeutic strategies. In the...
Source: Breast Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Yoshinami Source Type: research
Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
CONCLUSIONS: Incorporation of HER2-low category in HER2 status interpretation reduces the concordance rate between CNB and surgical resection specimens. Tumor multiplicity and ER positivity are predictive factors for conversion from HER2-zero to HER2-low status. Therefore, HER2 status should be re-evaluated in resection specimens when considering ADCs in tumors exhibiting multiplicity and ER positivity.PMID:38643429 | DOI:10.1007/s12282-024-01585-3 (Source: Breast Cancer)
Source: Breast Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Sei Na Milim Kim Yujun Park Hyun Jung Kwon Hee-Chul Shin Eun-Kyu Kim Mijung Jang Sun Mi Kim So Yeon Park Source Type: research
Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database
CONCLUSION: Among T2N1M0 stage HR + /HER2- patients, OS and BCSS of NACT were inferior to ACT. Patients who attained non-pCR after NACT demonstrated significantly worse survival outcomes compared with those who received ACT.PMID:38643430 | DOI:10.1007/s12282-024-01583-5 (Source: Breast Cancer)
Source: Breast Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Yuhang Shang Xuelian Wang Yansong Liu Weilun Cheng Yunqiang Duan Zhengbo Fang Jiangwei Liu Fanjing Kong Ting Wang Tianshui Yu Anbang Hu Jiarui Zhang Hanyu Zhang Mingcui Li Zhiyuan Rong Yanling Li Suborna S Shakila Xinxin Li Jianyuan Feng Fei Ma Baoliang G Source Type: research
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study
CONCLUSION: The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.PMID:38642245 | DOI:10.1007/s12282-024-01575-5 (Source: Breast Cancer)
Source: Breast Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Yoshinami Shigenori E Nagai Masaya Hattori Takuho Okamura Kenichi Watanabe Takahiro Nakayama Hiroko Masuda Michiko Tsuneizumi Daisuke Takabatake Michiko Harao Hiroshi Yoshino Natsuko Mori Hiroyuki Yasojima Chiya Oshiro Madoka Iwase Miki Yamaguch Source Type: research
French national survey on breast cancer care: caregiver and patient views
CONCLUSIONS: This study provides an updated analysis of breast cancer care pathways in France. Overall, the initial processes of diagnosis, announcement, and treatment were swift and were in agreement with the best care standards. No barriers to accessing care were identified. Based on the study findings, we proposed several strategies to improve the quality of care for patients in supportive care, coordination with primary care physicians, reconstructive surgery, and fertility preservation access.PMID:38635135 | DOI:10.1007/s12282-024-01576-4 (Source: Breast Cancer)
Source: Breast Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Christine Rousset-Jablonski Barbara Lortal Sophie Lantheaume Laurent Arnould H élène Simon Anne-Sophie Tuszynski M élanie Courtier Soukayna Debbah Marc Lefran çois Sita Balbin Anne-Sophie Kably Alain Toledano Source Type: research
